drugset
drugset / Trial / NCT01964872

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Participants

NCT01964872 ↗

Phase 1 Completed 84 enrolled Janssen Cilag N.V./S.A.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of single oral doses and multiple oral doses of JNJ-38877618 administered for 7 consecutive days in healthy adult male participants.

Timeline

Start
2013-11
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-38877618 Small molecule 6 mg Oral
Subject JNJ-38877618 Small molecule 1200 mg Oral

Indications

No indication recorded.